 Your new post is loading...
 Your new post is loading...
|
Scooped by
Ed Rybicki
January 22, 2016 5:07 AM
|
Sierra Leone confirmed a new case of Ebola on Wednesday, its second in less than a week, marking a further setback in efforts to end a two-year West African epidemic that has killed more than 11,300 people.
|
Scooped by
Ed Rybicki
January 18, 2016 7:54 AM
|
Named after the forest in Uganda from which it was first isolated in 1947, Zika virus (ZIKV) is a flavivirus transmitted by Aedes spp. mosquitos. Although the widespread distribution of the vector may make many regions vulnerable to ZIKV, the virus was confined to Africa and Asia until 2007, when it arrived in Oceania. However, in the past year, ZIKV has been circulating in the Americas, where concerns have now been raised over possible links with microcephaly (a congenital growth impairment of the head). During February–June 2014, an outbreak occurred on Easter Island, Chile, where ZIKV is thought to have been introduced by French Polynesians attending a cultural festival (Emerg. Infect. Dis. 21, 1887; 2015). In May 2015, Brazil confirmed the first cases of ZIKV to originate in the continental Americas, followed, in October–December, by Colombia, El Salvador, French Guiana, Guatemala, Honduras, Mexico, Panama, Paraguay, Suriname and Venezuela (PAHO, 23 Dec 2015). Outside of the Americas, the Atlantic island nation of Cape Verde announced its first ZIKV epidemic in October, with 4,744 suspected cases by 6 December (WHO, 21 Dec 2015). ZIKV is only rarely associated with severe disease requiring hospitalization. However, as of 28 November 2015, three deaths had been attributed to ZIKV in Brazil, including the death of a newborn with microcephaly. The ZIKV genome was detected in blood and tissue samples from this baby, and the Brazilian health ministry believes that ZIKV is linked to a 20-fold increase in cases of microcephaly in regions where the virus is circulating, and has warned of a risk to pregnant women (BBC News, 29 Nov 2015; PAHO, 1 Dec 2015). However, the CDC cautions that flaviviruses are not known to cause microcephaly, and that any possible association remains under investigation (CDC, 15 Dec 2015).
|
Scooped by
Ed Rybicki
January 16, 2016 7:27 AM
|
|
Scooped by
Ed Rybicki
January 16, 2016 6:29 AM
|
Transmission of the virus has been stopped in West Africa – but what has the world learned?
|
Scooped by
Ed Rybicki
January 8, 2016 3:16 PM
|
RNAs are functionally diverse macromolecules whose proper functions rely strictly upon their correct tertiary structures. However, because of their high structural flexibility, correct folding of RNAs is challenging and slow. Therefore, cells and viruses encode a variety of RNA remodeling proteins, including helicases and RNA chaperones. In RNA viruses, these proteins are believed to play pivotal roles in all the processes involving viral RNAs during the life cycle. RNA helicases have been studied extensively for decades, whereas RNA chaperones, particularly virus-encoded RNA chaperones, are often overlooked. This review describes the activities of RNA chaperones encoded by RNA viruses, particularly the ones identified and characterized in recent years, and the functions of these proteins in different steps of viral life cycles, and presents an overview of this unique group of proteins.
|
Scooped by
Ed Rybicki
December 31, 2015 2:15 AM
|
Coronaviruses: emerging and re-emerging pathogens in humans and animals Edited by Susanna K. P. Lau Some of the coronavirus infections raise very serious problems in the past 2 decades, such as the severe acute respiratory syndrome (SARS) outbreak in 2003, and porcine epidemic diarrhea virus (PEDV) which has caused millions of deaths in piglets worldwide. More recently, we are threatened by the outbreak of Middle East respiratory syndrome (MERS) which has spread to various countries including South Korea. This thematic series published in Virology Journal emphasizes advances and key discoveries in the animal origin, viral evolution, epidemiology, diagnostics and pathogenesis of different emerging and re-emerging coronaviruses. Click here to view the call for papers.
|
Scooped by
Ed Rybicki
December 30, 2015 6:12 AM
|
Zombies—also known as walkers, Zed, Zs, biters, geeks, stiffs, roamers, Zeke, ghouls, rotters, Zoms, and runners—have become a dominant part of the medical landscape. Zombie expert Matt Mogk defines a zombie with three criteria: it is a reanimated human corpse; it is relentlessly aggressive; and it is biologically infected and infectious.1 But Mogk notes that this definition has been altered by the recognition of “rage” zombies, which are infected but still alive. They are more closely related to vampires infected with the contagious bacterium Bacillus vampiris.2 Here, I review zombie biology and epidemiology.
|
Scooped by
Ed Rybicki
December 15, 2015 5:25 AM
|
How best to use antiretroviral therapy (ART) has been a topic of debate for almost three decades. The landmark START trial1 settled one question that should have been resolved long ago—when to initiate ART in people with HIV. Findings of START showed a 57% reduction in AIDS, severe non-AIDS events, or deaths in people with a CD4 count higher than 500 cells/μL who were randomly assigned to immediate versus deferred treatment.2 This finding supports conclusions from observational studies and the recently completed west African TEMPRANO trial3 (which also favoured early treatment), and has profound implications for public health.
|
Scooped by
Ed Rybicki
December 15, 2015 5:23 AM
|
Although human Middle-East respiratory syndrome coronavirus (MERS-CoV) infection seems to be associated with exposure to animals, including camels, identification of the animal reservoir remains challenging.1–3 We believe that this gap results from the fact that surveillance systems for diseases in both human beings and animals remain fragmented and fail to take into account the social and ecological contexts within which diseases emerge. Additionally, there is a paucity of data for emerging infectious diseases in animals, especially camels in east Africa.
|
Scooped by
Ed Rybicki
December 11, 2015 12:26 PM
|
Most of South Africa – and the world for that matter – has thus far relied on a short statement from the Presidency to try understand President Jacob Zuma’s ir-rationale for firing respected Finance Minister Nhlanhla Nene. But as globally respected author and journalist Rian Malan explains in this brilliant contribution, most have thus far missed what was surely Zuma’s version of PW Botha’s Rubicon Speech. Like Botha did 30 years ago, Zuma deviated completely from the original script. Instead, he produced almost an hour of ad-libbing, providing a window into the mind of a man we can all now see is massively out of his depth. Now that he has been given his head it’s quite obvious that Zuma possesses none of the basics required to drive a complex modern economy, least of all the critical requirement of an open mind. A year ago, almost to the day, we published Rian Malan’s take on EFF leader Julius Malema. It quickly became one of our best read stories of 2014. There’s no doubt the army of Rian Malan fans will appreciate this superb piece just as much. It is republished with the permission of Politicsweb where it first appeared. – Alec Hogg
|
Scooped by
Ed Rybicki
December 11, 2015 2:41 AM
|
If I had gotten the flu shot the year I was pregnant I would have… Been the first person to hold my child Taken him to his first checkup Had a tearful and joyful first few minutes as a new family of three Been the first person to rock my son to sleep Given him his first kiss Breastfed my baby The ability to have more kids
|
Scooped by
Ed Rybicki
December 10, 2015 9:02 AM
|
A wave of new therapies on the horizon
View the articles at the bottom of this article
2015 marks the 50th anniversary of the discovery of the Australia antigen, which in 1967 was identified to be the hepatitis B virus surface antigen. Although much has been accomplished over the past five decades, current antiviral therapies for chronic hepatitis B only achieve the sustained clearance of infection in a minority of patients. Recent success in using combinations of drugs to cure almost all cases of chronic hepatitis C has stimulated interest in a similar approach to chronic hepatitis B. We are proud to present you the Hepatitis B Symposium. This joint project of Antiviral Research with the Hepatitis B Foundation offers you the latest research on the history, pathophysiology and current management of hepatitis B. It also describes a wave of newly identified drug targets, investigational compounds and experimental strategies that are now under clinical evaluation or in preclinical development. The Hepatitis B Foundation is a non-profit organization that has been dedicated to the global problem of hepatitis B for almost 25 years. Its commitments include funding focused research, promoting disease awareness, supporting immunization and treatment initiatives, and serving as the primary source of information for patients and their families, the medical and the scientific community, and the general public.
Thirty young men spent months burning the bodies of the infected. A year later, many relatives and fellow countrymen still can’t forgive them.
Via Ian M Mackay, PhD
|
|
Scooped by
Ed Rybicki
January 18, 2016 7:58 AM
|
Herpes simplex virus establishes latent infection in peripheral neurons, and neuronal stress is known to reactivate virus production, but the molecular mechanisms underlying reactivation are unclear. Cliffe et al. now show that a neuron-specific Jun N-terminal kinase (JNK) stress pathway activates the expression of latent herpes simplex virus. Herpesvirus graphic courtesy of Russell Kightley Media
|
Scooped by
Ed Rybicki
January 18, 2016 7:12 AM
|
It is widely accepted that effective human immunodeficiency virus (HIV) vaccines need to elicit a range of responses, including neutralising antibodies and T-cells. In natural HIV infections, immune responses to Gag are associated with lower viral load in infected individuals, and these responses can be measured against infected cells before the replication of HIV. Priming immune responses to Gag with DNA or recombinant Bacillus Calmette-Guérin (BCG) vaccines, and boosting with Gag virus-like particles as subunit vaccines or Gag produced in vivo by other vaccine vectors, elicits high-magnitude, broad polyfunctional responses, with memory T-cell responses appropriate for virus control. This review provides justification for the inclusion of HIV Gag in vaccine regimens, either as a transgene expressing protein that may assemble to form budded particles, or as purified virus-like particles. Possible benefits would include early control via CD8(+) T-cells at the site of infection, control of spread from the entry portal, and control of viraemia if infection is established.
|
Scooped by
Ed Rybicki
January 16, 2016 7:09 AM
|
A look at how phage therapy differs from antibiotic treatment
|
Scooped by
Ed Rybicki
January 16, 2016 6:28 AM
|
Researchers aim to prevent recurrences by finding the virus’s natural host.
|
Scooped by
Ed Rybicki
December 31, 2015 3:51 AM
|
Mosquito-borne disease affecting millions has had no approved vaccine until now
|
Scooped by
Ed Rybicki
December 31, 2015 1:52 AM
|
Very funny tongue-in-cheek responses to the zombie article
|
Scooped by
Ed Rybicki
December 15, 2015 5:27 AM
|
Added value of this study This study constitutes the first phase 1 report of monovalent ChAd3-EBO-Z vaccine in west Africans and compares four doses, consisting of 1 × 1010 particle units (pu), 2·5 × 1010 pu, 5 × 1010 pu, and 1 × 1011 pu. The results in both Malian and US participants document that the 1 × 1011 pu dose is well tolerated and significantly more immunogenic than are low doses in elicitation of antiglycoprotein antibodies measured with ELISA. 91% of Malian and 60% of US participants given a single dose of ChAd3-EBO-Z attained titres that are associated with protection of NHPs against lethal challenge with wild-type Zaire Ebola virus, suggesting, by extrapolation, that this dose could protect humans against natural infection. A single booster dose of modified vaccinia Ankara expressing Zaire Ebola virus glycoprotein stimulated anamnestic antiglycoprotein antibody and CD4 and CD8 T-cell responses to glycoprotein peptides, suggesting, by extrapolation from results in NHPs, that this booster might extend the duration of high-level protection. Implications of all the available evidence With optimistic extrapolation of these results, a single 1 × 1011 pu dose of ChAd3-EBO-Z might be sufficiently well tolerated and immunogenic to be effective in interruption of transmission of Ebola virus to family members and other close contacts of index patients if used in a ring vaccination tactic after rapid identification of cases. A heterologous prime and boost regimen consisting of a ChAd3-EBO-Z prime followed 2–3 months afterwards by a boost with modified vaccinia Ankara expressing Zaire Ebola virus glycoprotein could confer long-term protection to subgroups (eg, health-care and front-line workers) that need extended protection.
|
Scooped by
Ed Rybicki
December 15, 2015 5:24 AM
|
Since the beginning of the century, the number of measles-related deaths has fallen substantially; between 2000 and 2014 mass immunisation efforts prevented an estimated 17·1 million deaths worldwide, and the number of cases decreased from 146 to 40 per million. Unfortunately, after this decrease the situation has stagnated and many countries are falling far behind the 2015 elimination targets according to a report by WHO and the US Centers for Disease Control and Prevention (CDC) released in November, 2015. The elimination target was to reduce rates of measles virus infection to fewer than five cases per million people, as well as to reduce worldwide mortality rates by 95% from the 2000 estimate. By contrast, the report points out that although in all countries immunisation schedules include at least one dose of measles-containing vaccine, by 2014 only 122 countries—compared with 131 in 2012—met the target of at least 90% of children receiving the first dose. Moreover, only half the world is receiving the recommended second dose of the vaccine.
|
Scooped by
Ed Rybicki
December 15, 2015 5:22 AM
|
In The Lancet Infectious Diseases, Milagritos Tapia and colleagues1 address two important facets of Ebola virus immunity: longevity of vaccine-induced immune responses and correlates of immunity. Early attempts at Ebola virus vaccines on the basis of traditional methods, such as inactivated preparations and subunit vaccines, were not effective in animal studies2 (although later publications on these platforms are more promising3). Subsequent studies used a wide diversity of vaccine platforms that had not been used in approved human vaccines, such as non-pathogenic viral vectors engineered to express Ebola virus surface glycoprotein.4
|
Scooped by
Ed Rybicki
December 11, 2015 2:51 AM
|
The U.S. Food and Drug Administration has given the thumbs up to a genetically modified chicken that produces a drug in its eggs. It’s the latest addition to a growing area in medicine known as “farmaceuticals.” The drug is called Kanuma, or sebelipase alfa, and it’s used to treat a rare and devastating disease known as lysomal acid lipase deficiency (or LAL deficiency). This heritable condition prevents the body from breaking down fatty molecules in cells, including those in the liver, spleen, and vasculature. Kanuma, a recombinant human enzyme marketed by Alexion Pharmaceuticals, replaces the faulty enzyme responsible for the disorder, which is often fatal in infants. A second form of the disorder also exists in adults, causing liver enlargement, fibrosis, cirrhosis, and cardiovascular disease.
|
Scooped by
Ed Rybicki
December 10, 2015 9:36 AM
|
The means of engineering potentially deadly avian influenza is freely available on the internet. Despite continuing global efforts to contain avian influenza, or bird flu, the means of engineering this potentially deadly H5N1 virus to render it transmissible to humans is freely available on the internet. So too are similar instructions for engineering a virus like the "Spanish flu", which killed some 50 million people in the pandemic of 1918-19. The digital floodgates opened in 2011 when a peak US regulatory watchdog came down in favour of scientists seeking to publishing their work engineering the H5N1 virus. The decision to uphold such "scientific freedom" was and remains, highly contentious among the global scientific community. Its implications, however, are readily available as online "recipes" for potentially dangerous viruses, which add a new risk to the already considerable challenges of maintaining global biosecurity in the 21st century. For all the recent advances in biomedical science, drugs, vaccines and technology, this is a challenge we remain ill-equipped to meet.
Read more: http://www.theage.com.au/comment/online-recipes-for-contagious-diseases-means-australias-bioterrorism-threat-is-real-20151208-gli97v.html#ixzz3tvWn63AE Follow us: @theage on Twitter | theageAustralia on Facebook
|
Scooped by
Ed Rybicki
December 10, 2015 8:08 AM
|
The movie Contagion showed the havoc a virus could spread. This virus was based on a real virus - which does not spread as easily as in the movie, but is as deadly.
|
Ah, the perils of declaring a country Ebola-free...inadvisable!